TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area under the plasma concentration time curve from time zero to the time of the last quantifiable concentration (AUC[0-T])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in SARS-CoV-2 log viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Area under the plasma drug concentration - time curve from zero to the end of the dosing interval (AUC[0-tlast])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Faces Pain Scale- Revised (FPS-R)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Accuracy of the mobile health application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Precision of the mobile health application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Wrinkles/photoaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Model interchangeability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in malondialdehyde (MDA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visual Patient Satisfaction Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Taiwanese Version of Frontal Assessment Battery (TFAB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Wechsler Memory Scale-Third Edition (WMS-III)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Improvement in DRSS score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Platelet transfusion responsiveness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in Gastro-Esophageal Reflux Disease (GERD) severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall Response Rate (ORR) at Cycle 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Binocular distance corrected visual acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Skin Picking Scale - Revised (SPS-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Inventory of Depressive Symptomatology - Clinician Rated
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Delis Kaplan Executive Function System Letter Fluency
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Peptide concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Saliva pH measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum GSK1070806 area under the concentration-time curve from time zero extrapolated to infinity (AUC[0-∞])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed serum concentration (Cmax) of GSK1070806
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Co-parenting Behavior
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Occurrence of treatment-limiting toxicities (TLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of screening: screened to eligible ratio
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of enrollment: eligible to enrollment ratio
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of retention: retention at each assessment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of interventions: attendance rates for each session
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of survey completion: survey completion rates at each assessment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Scoliosis correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of pCR
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in scores on quality of life assessments
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in scores on functional outcome assessments
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Pain relief at 2 hours post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the Mi-Helper device
Endpoint domain: Adverse events/effects
Primary endpoint: Tolerability of the Mi-Helper device
Endpoint domain: Adverse events/effects
Primary endpoint: Limp Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sit to Reach Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of Serious Adverse Event (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: myokine concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recurrence-free survival (RFS) at one year
Endpoint domain: Mortality/survival
Primary endpoint: Pain at rest and during defecation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: beta hCG results of the transferred embryos
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Biochemical analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Hormone analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Microvascular diameter
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microvascular turtuosity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Hypotension and Bradycardia Intraoperative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Phenyl ethyl alcohol odor detection threshold
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Traditional Chinese version of University of Pennsylvania Smell Identification Test (TC-UPSIT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lymph node (LN) tissue penetration ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Lymph node (LN) residual viremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Altered states of consciousness profile
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Overall Incidence of perineal trauma
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of different degree of perineal trauma
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of different subgroup of second-degree perineal trauma
Endpoint domain: Adverse events/effects
Primary endpoint: Safety and tolerability of ZM-H1505R
Endpoint domain: Adverse events/effects
Primary endpoint: Depression risk factors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Anxiety risk factors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Eating disorder risk factors
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Changes in average daily step counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in average daily sedentary time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in average daily light-intensity physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in average daily moderate-vigorous intensity physical activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Correction of hypernatremia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to neurodevelopment disorder diagnostic
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Maximum Observed Concentration (Cmax) of BOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) of BOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve From Time 0 to Infinity (AUC∞) of BOS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma levels of biological markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in procalcitonin level (ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in antimicrobial peptide cathelicidin (LL37) level (ng/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in weight (percentage of total weight)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in fat mass (percent)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in fat mass (kilograms)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Oral Feeding
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Meniscal blood supply
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of participants with clinically significant changes in ECOG performance status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants with clinically significant changes in hematology and clinical chemistry parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Disability rating-scale for severe head trauma (DRS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Harvard Breast Cosmesis Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Postoperative neck edema Incidence rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative short-term pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants achieving body weight reduction greater than or equal to 5%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of mesoangioblasts ex vivo isolated from muscle biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proliferation capacity of mesoangioblasts in vitro
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Myogenic capacity of mesoangioblasts in vitro
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cure of the disease
Endpoint domain: Mortality/survival
Primary endpoint: Change in gut microbiome profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: waist-to-height ratio (WHtR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Adherence to lifestyle recommendations
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Dichomatized modified Rankin Scale (mRS)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Disease Activity Evaluation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Discontinuations due to Adverse Event(s) (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Prescribing Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Peak arterio-venous oxygen content difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Difference in treatment recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Prevalence of Intimate Partner Violence
Endpoint domain: Adverse events/effects
Primary endpoint: Geometric Mean of AUC of Antibody Against WA-1 S2-P for Cohort 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Geometric Mean of Pseudovirus Neutralization Against D614G for Cohort 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percent of Participants Who Seroconverted Against WA-1 S2-P for Cohort 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in plasma amyloid-beta 42 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Diagnosis of persistent asthma
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Clinical improvement of pain and pelvic symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC last of Losartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: t1/2 of Losartan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global longitudinal Strain (GLS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of pregnant women with maternal adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of women with obstetrical adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of participants with adverse pregnancy outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of offsprings with neonatal adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of offsprings with infant adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Vital signs - Blood pressure value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vital signs - Pulse value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Vital signs - Respiratory value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Changes in carotid IMT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Change in Condomless Receptive Sex Acts
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Area Under the Concentration-Time Curve (AUC 0-22 weeks)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Data set creation
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Squamous Cell Carcinoma Antigen2 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Shoulder Instability Return to Sport Index (SIRSI)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Interleukin - 1b levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Interleukin - 6 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: White blood cell total count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in cervical range of motion (ROM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in Endocrine Disrupting Chemical (EDC) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Efficiency of UDFF for hepatic steatosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Weight change response to bariatric surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in eczema severity based on the Patient Oriented Eczema Measure (POEM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in eczema severity based on the Eczema Area and Severity Index (EASI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in the severity of itch
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline in Negative Emotional Bias
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline in Cognitive Fluctuations
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Occurrence of psychiatric RPD
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Loneliness measured by UCLA-LS
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Prednisolone concentration levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation of the vasculature pattern of the bronchial mucosa
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: AFROC-AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Attendance of second round of mammography follow up
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Prevalence of septic arthritis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Anteroposterior position changes of upper first molars
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Securis™ Stabilization Device Securement Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Percentage of Participants with Select Skin Conditions
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Confirmed Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: sFlt-1/PlGF ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GCT result
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of abnormal laparoscopic and hysteroscopic findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonatal Morbidity and Mortality Rate
Endpoint domain: Mortality/survival
Primary endpoint: Area under operating characteristic curves (AUC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intradialytic muscle cramp (severity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: intradialytic muscle cramp (duration)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Radiation dose to major organs and tumors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of dental plaque detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative conversion or relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Accuracy of AI-Driven Virtual Biopsy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Median Time to Sustained Symptom Resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion rate of chemotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: sST2 predictive value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance visual acuity using DDVIT vision test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Distance visual acuity using ETDRS vision test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: safety of the combination of FLIRT-bevacizumab
Endpoint domain: Adverse events/effects
Primary endpoint: recommended phase 2 dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient safety competence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall objective response rates (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of positive PCR test for SARS-COV2
Endpoint domain: Adverse events/effects
Primary endpoint: System Performance Accuracy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NMB usage
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Peripheral Oxygen Saturation (SpO2)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Anxiety disorder level evaluation
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Outpatient Clinic Attendance Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in the Problem Areas in Diabetes Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Rate of responders based on aesthetic improvement of NLFs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of adolescent women referred
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Biochemically verified continuous smoking abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Who Completed the Trial
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Time until first occurrence
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants who survive with a functional graft with eGFR > 30 mL/min/1.73 m2
Endpoint domain: Mortality/survival